Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1970 1
1971 3
1972 3
1973 2
1974 3
1975 6
1976 3
1977 2
1978 4
1979 3
1980 7
1981 4
1982 5
1983 1
1984 1
1985 4
1986 3
1987 2
1988 1
1990 1
1991 5
1992 5
1993 3
1994 1
1995 4
1996 7
1997 11
1998 9
1999 14
2000 8
2001 12
2002 8
2003 14
2004 13
2005 16
2006 17
2007 22
2008 26
2009 18
2010 15
2011 24
2012 25
2013 26
2014 49
2015 52
2016 76
2017 84
2018 142
2019 186
2020 225
2021 304
2022 338
2023 333
2024 378
2025 204

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

2,430 results

Results by year

Filters applied: . Clear all
Page 1
[A mini-review on anti-tumor effect of cannabidiol].
Xie R, Hao DL, Yang JY, Jia LY, Wang PQ, Zhao Y, Chen YJ, Zhao QH. Xie R, et al. Zhongguo Zhong Yao Za Zhi. 2022 Dec;47(24):6541-6550. doi: 10.19540/j.cnki.cjcmm.20220906.601. Zhongguo Zhong Yao Za Zhi. 2022. PMID: 36604902 Review. Chinese.
Cannabidiol is the main non-psychoactive component of Cannabis sativa, which has multiple medicinal activities, such as antiepileptic, immunomodulation, analgesic, antioxidant, anticonvulsant, anti-anxiety and other functions. ...
Cannabidiol is the main non-psychoactive component of Cannabis sativa, which has multiple medicinal activities, such as antiepileptic …
Marijuana for Glaucoma: A Recipe for Disaster or Treatment?
Sun X, Xu CS, Chadha N, Chen A, Liu J. Sun X, et al. Yale J Biol Med. 2015 Sep 3;88(3):265-9. eCollection 2015 Sep. Yale J Biol Med. 2015. PMID: 26339209 Free PMC article. Review.
Use of marijuana to lower IOP as a means of glaucoma treatment would require frequent use throughout the day, leading to significant adverse effects, possible progression toward Cannabis Use Disorder (CUD), and/or withdrawal symptoms. The treatment of glaucoma based on the …
Use of marijuana to lower IOP as a means of glaucoma treatment would require frequent use throughout the day, leading to significant adverse …
[Medicinal chemistry and pharmacology focused on cannabidiol, a major component of the fiber-type cannabis].
Takeda S. Takeda S. Yakugaku Zasshi. 2013;133(10):1093-101. doi: 10.1248/yakushi.13-00196. Yakugaku Zasshi. 2013. PMID: 24088353 Free article. Review. Japanese.
Considerable attention has focused on cannabidiol (CBD), a major non-psychotropic constituent of fiber-type cannabis plant, and it has been reported to possess diverse biological activities. Although CBD is obtained from non-enzymatic decarboxylation of its parent molecule …
Considerable attention has focused on cannabidiol (CBD), a major non-psychotropic constituent of fiber-type cannabis plant, and it ha …
Comparative metabolism of THCA and THCV using UHPLC-Q-Exactive Orbitrap-MS.
Rao Q, Zhang T, Pu QL, Li B, Zhao Q, Yan DM, Wu ZE, Li F. Rao Q, et al. Xenobiotica. 2023 Jan;53(1):46-59. doi: 10.1080/00498254.2023.2194981. Epub 2023 Apr 10. Xenobiotica. 2023. PMID: 36951512
Delta(9)-tetrahydrocannabinolic acid (THCA) and delta(9)-tetrahydrocannabivarin (THCV) are phytocannabinoids with a similar structure derived from Cannabis sativa and possess a variety of biological activities. However, the relationship between the metabolic characterisati …
Delta(9)-tetrahydrocannabinolic acid (THCA) and delta(9)-tetrahydrocannabivarin (THCV) are phytocannabinoids with a similar structure derive …
Cannabis and Craniotomy for Glioblastoma: Impact on Complications and Health Care Utilization.
Sreenivasan S, Kaoutzani L, Ugiliweneza B, Boakye M, Schulder M, Sharma M. Sreenivasan S, et al. World Neurosurg. 2024 Oct;190:e707-e715. doi: 10.1016/j.wneu.2024.07.210. Epub 2024 Aug 5. World Neurosurg. 2024. PMID: 39111656
In the United States, 52.5 million people 12 years of age used cannabis in 2021. We aim to elucidate differences in complications after craniotomy for resection of GBM between users and nonusers of cannabis. ...CONCLUSIONS: This retrospective population-based study …
In the United States, 52.5 million people 12 years of age used cannabis in 2021. We aim to elucidate differences in complications aft …
Substance Use Disorders Are Independently Associated with Hospital Readmission Among Patients with Brain Tumors.
Jimenez AE, Cicalese KV, Chakravarti S, Porras JL, Azad TD, Jackson CM, Gallia G, Bettegowda C, Weingart J, Mukherjee D. Jimenez AE, et al. World Neurosurg. 2022 Oct;166:e358-e368. doi: 10.1016/j.wneu.2022.07.006. Epub 2022 Jul 8. World Neurosurg. 2022. PMID: 35817348
BACKGROUND: Research on the effects of substance use disorders (SUDs) on postoperative outcomes within neurosurgical oncology has been limited. Therefore, the present study sought to quantify the effect of having a SUD on hospital length of stay, postoperative complication …
BACKGROUND: Research on the effects of substance use disorders (SUDs) on postoperative outcomes within neurosurgical oncology has bee …
The impact of cannabis use disorder on urologic oncologic surgery morbidity, length of stay, and inpatient cost: analysis of the National Inpatient Sample from 2003 to 2014.
Tinsley SA, Arora S, Stephens A, Finati M, Chiarelli G, Cirulli GO, Morrison C, Richard C, Hares K, Rogers CG, Abdollah F. Tinsley SA, et al. World J Urol. 2024 Aug 2;42(1):465. doi: 10.1007/s00345-024-05151-6. World J Urol. 2024. PMID: 39090376
PURPOSE: This study examined the impact of cannabis use disorder (CUD) on inpatient morbidity, length of stay (LOS), and inpatient cost (IC) of patients undergoing urologic oncologic surgery. ...
PURPOSE: This study examined the impact of cannabis use disorder (CUD) on inpatient morbidity, length of stay (LOS), and inpatient co …
The Association between Monthly, Yearly, and Lifetime Cannabis Use, and Semen Parameters in Asian-American Men.
Belladelli F, Chen T, Basran S, Greenberg DR, Del Giudice F, Mulloy E, Chen CH, Cheng YS, Salonia A, Eisenberg ML. Belladelli F, et al. World J Mens Health. 2023 Jul;41(3):623-630. doi: 10.5534/wjmh.220106. Epub 2022 Aug 29. World J Mens Health. 2023. PMID: 36047080 Free PMC article.
RESULTS: Among the 112 men included in this study, 51 used cannabis at least once in their lifetime, 30 men used cannabis at least once in the last 12 months, and 26 men used cannabis at least once in the last 30 days. ...However, when stratifying by subferti …
RESULTS: Among the 112 men included in this study, 51 used cannabis at least once in their lifetime, 30 men used cannabis at l …
Cannabis use disorder and severe sepsis outcomes in cancer patients: Insights from a national inpatient sample.
Sager AR, Desai R, Mylavarapu M, Shastri D, Devaprasad N, Thiagarajan SN, Chandramohan D, Agrawal A, Gada U, Jain A. Sager AR, et al. World J Crit Care Med. 2025 Jun 9;14(2):100844. doi: 10.5492/wjccm.v14.i2.100844. eCollection 2025 Jun 9. World J Crit Care Med. 2025. PMID: 40491879 Free PMC article.
BACKGROUND: The burden of cannabis use disorder (CUD) in the context of its prevalence and subsequent cardiopulmonary outcomes among cancer patients with severe sepsis is unclear. AIM: To address this knowledge gap, especially due to rising patterns of cannabis …
BACKGROUND: The burden of cannabis use disorder (CUD) in the context of its prevalence and subsequent cardiopulmonary outcomes among …
Thromboembolic events in metastatic testicular cancer treated with cisplatin-based chemotherapy.
Shields LBE, Daniels MW, Mar N, Rezazadeh Kalebasty A. Shields LBE, et al. World J Clin Oncol. 2021 Mar 24;12(3):183-194. doi: 10.5306/wjco.v12.i3.183. World J Clin Oncol. 2021. PMID: 33767973 Free PMC article.
BACKGROUND: Testicular germ cell tumor (TGCT) is the most curable solid tumor and most common cancer among men 18-39 years. While cisplatin-based chemotherapy has significantly lengthened the survival of patients with TGCT, it is associated with a high rate of thromboembol …
BACKGROUND: Testicular germ cell tumor (TGCT) is the most curable solid tumor and most common cancer among men 18-39 years. While cis …
Medicinal Cannabis and Implications for Workplace Health and Safety: Scoping Review of Systematic Reviews.
O'Neill V, Karanikas N, Sav A, Murphy P. O'Neill V, et al. Workplace Health Saf. 2023 Sep;71(9):400-410. doi: 10.1177/21650799231157086. Epub 2023 Apr 19. Workplace Health Saf. 2023. PMID: 37077169 Free PMC article.
PURPOSE: Although medicinal cannabis is prescribed for conditions such as pain, epilepsy, nausea and vomiting during cancer treatment, evidence about associated adverse side effects is still evolving. ...This study aimed to map the types and prevalence of the AEs as …
PURPOSE: Although medicinal cannabis is prescribed for conditions such as pain, epilepsy, nausea and vomiting during cancer tr …
The evolution of cannabinoid receptors in cancer.
Pennant NM, Hinton CV. Pennant NM, et al. WIREs Mech Dis. 2023 Jul-Aug;15(4):e1602. doi: 10.1002/wsbm.1602. Epub 2023 Feb 7. WIREs Mech Dis. 2023. PMID: 36750231 Free PMC article. Review.
Cannabis sativa (cannabis) has been used as a therapeutic treatment for centuries treating various diseases and disorders. ...Cannabinoids have been shown to inhibit proliferation, metastasis, and angiogenesis and even restore homeostasis in a variety of models of …
Cannabis sativa (cannabis) has been used as a therapeutic treatment for centuries treating various diseases and disorders. ... …
Does cannabis elevate cancer risk? : Evidence from Mendelian randomization.
Niu D, Li C, Qu H, Zheng Y. Niu D, et al. Wien Klin Wochenschr. 2024 Jun;136(11-12):311-318. doi: 10.1007/s00508-023-02303-3. Epub 2023 Nov 10. Wien Klin Wochenschr. 2024. PMID: 37947877
BACKGROUND: Cannabis use is increasing annually but the relationship between cannabis use and cancer incidence is not uniform because of confounding factors. ...CONCLUSION: Large MR analyses suggest that lifetime cannabis use may reduce breast cance …
BACKGROUND: Cannabis use is increasing annually but the relationship between cannabis use and cancer incidence is not u …
[Pain management in view of current new legislative updates and their practical consequences in Austria].
Fazeny B, Muhm M, Berzlanovich A, Wenzel C, Hagmeister H, Marosi C. Fazeny B, et al. Wien Klin Wochenschr. 2000 Apr 21;112(8):372-5. Wien Klin Wochenschr. 2000. PMID: 10849945 Review. German.
Although the WHO edited guidelines for pain treatment as early as 1986, practical management has frequently remained inadequate, especially in cancer patients. Traditional adherence to restrictions from the former Austrian Controlled Drug Act which have resulted in ongoing …
Although the WHO edited guidelines for pain treatment as early as 1986, practical management has frequently remained inadequate, especially …
Medical marijuana.
Marmor JB. Marmor JB. West J Med. 1998 Jun;168(6):540-3. West J Med. 1998. PMID: 9656007 Free PMC article. Review.
[Results of examining the population in a region with high morbidity for oral mucosal cancer: precancerous changes].
Zaridze DG, Matiakin EG, Poliakov BI, Khamrakulov FS, Trapeznikov NN. Zaridze DG, et al. Vopr Onkol. 1987;33(2):38-41. Vopr Onkol. 1987. PMID: 2950660 Russian.
Interviewing and examination of a population characterized by a high level of morbidity of oral cavity cancer, supposedly induced by the use of nas, established a high incidence of leukoplakia and preleukoplakia at this site which are identified as precancerous lesions. .. …
Interviewing and examination of a population characterized by a high level of morbidity of oral cavity cancer, supposedly induced by …
In Vitro Antitumor Effect of Oils Rich in CBD and THC Cannabis Extract in Canine Prostate Carcinoma Cell Lines.
Calheiros LGRM, Pedro G, Oliveira da Silva T, Amorim RM, Alves CEF, Laufer-Amorim R. Calheiros LGRM, et al. Vet Sci. 2024 Oct 13;11(10):501. doi: 10.3390/vetsci11100501. Vet Sci. 2024. PMID: 39453093 Free PMC article.
Prostate cancer is one of the leading causes of cancer-related deaths worldwide, even when diagnosed at an early stage in humans and dogs. Dogs have a significant incidence of spontaneous prostate cancer, which is highly similar to human androgen-independent …
Prostate cancer is one of the leading causes of cancer-related deaths worldwide, even when diagnosed at an early stage in huma …
Cannabidiol and the possibilities of its use in veterinary medicine of dogs and horses: A brief review.
Landa L, Trojan V, Demlova R, Jurica J, Hrib R. Landa L, et al. Vet Med (Praha). 2022 Jun 17;67(9):455-462. doi: 10.17221/127/2021-VETMED. eCollection 2022 Jun. Vet Med (Praha). 2022. PMID: 38715968 Free PMC article. Review.
Presently, it is not possible to use medical marijuana (in terms of the dried cannabis flowers) for veterinary purposes in many countries, but there is increasing evidence that isolated cannabinoids also have beneficial effects (namely cannabidiol - CBD). ...
Presently, it is not possible to use medical marijuana (in terms of the dried cannabis flowers) for veterinary purposes in many count …
The effect of cannabidiol on canine neoplastic cell proliferation and mitogen-activated protein kinase activation during autophagy and apoptosis.
Henry JG, Shoemaker G, Prieto JM, Hannon MB, Wakshlag JJ. Henry JG, et al. Vet Comp Oncol. 2021 Jun;19(2):253-265. doi: 10.1111/vco.12669. Epub 2021 Jan 14. Vet Comp Oncol. 2021. PMID: 33247539
Low tetrahydrocannabinol Cannabis sativa products, also known as hemp products, have become widely available and their use in veterinary patients has become increasingly popular. ...CBD significantly reduced canine cancer cell proliferation far better than CBDA acro …
Low tetrahydrocannabinol Cannabis sativa products, also known as hemp products, have become widely available and their use in veterin …
Marijuana, Lower Urinary Tract Symptoms, and Pain in the Urologic Patient.
Pham MN, Hudnall MT, Nadler RB. Pham MN, et al. Urology. 2020 May;139:8-13. doi: 10.1016/j.urology.2020.01.029. Epub 2020 Feb 4. Urology. 2020. PMID: 32027882 Review.
Cannabinoids have mixed efficacy for neurogenic LUTS and little evidence for non-neurogenic LUTS, chronic non-cancer-related and perioperative pain. For cancer-related pain, high-level studies demonstrate cannabinoids are well-tolerated with unclear benefit. ...
Cannabinoids have mixed efficacy for neurogenic LUTS and little evidence for non-neurogenic LUTS, chronic non-cancer-related and peri …
Association between cannabis use and the risk of bladder cancer: results from the California Men's Health Study.
Thomas AA, Wallner LP, Quinn VP, Slezak J, Van Den Eeden SK, Chien GW, Jacobsen SJ. Thomas AA, et al. Urology. 2015 Feb;85(2):388-92. doi: 10.1016/j.urology.2014.08.060. Epub 2014 Nov 1. Urology. 2015. PMID: 25623697
OBJECTIVE: To investigate the association of cannabis use and tobacco smoking on the incidence of bladder cancer within the California Men's Health Study cohort. ...Men were followed over an 11-year period and 279 (0.3%) developed incident bladder tumors. Among c …
OBJECTIVE: To investigate the association of cannabis use and tobacco smoking on the incidence of bladder cancer within the Ca …
[Cannabinoid therapy in practice].
Rasche T, Emmert D, Stieber C, Mücke M, Conrad R. Rasche T, et al. Urologe A. 2018 May;57(5):558-562. doi: 10.1007/s00120-018-0636-0. Urologe A. 2018. PMID: 29651709 Review. German.
BACKGROUND: In recent years, the media and scientists have shown increased interest in cannabis-based drugs. OBJECTIVES: Background information about cannabis-based drugs and their mechanism of action as well as discussion of possible applications as supportive ther …
BACKGROUND: In recent years, the media and scientists have shown increased interest in cannabis-based drugs. OBJECTIVES: Background i …
A population-level analysis on the association of cannabis use and urologic cancers.
Davis RJ, Hershenhouse J, Gallagher TJ, Sabharwal N, Daneshvar MA. Davis RJ, et al. Urol Oncol. 2025 Jun 7:S1078-1439(25)00205-4. doi: 10.1016/j.urolonc.2025.05.010. Online ahead of print. Urol Oncol. 2025. PMID: 40484779 Free article.
Utilizing risk ratios, we assessed risk of developing bladder, kidney, prostate, upper tract, testis, and penile cancer any time after cannabis diagnosis. RESULTS: Following exclusion, 74,642 patients with and 4,709,585 without cannabis dependence or abuse we …
Utilizing risk ratios, we assessed risk of developing bladder, kidney, prostate, upper tract, testis, and penile cancer any time afte …
[Cannabis is not for children or adolescents].
Opstrup P, Olsen M, Nysom K, Uldall PV, Walther-Larsen S. Opstrup P, et al. Ugeskr Laeger. 2017 Oct 16;179(42):V07170527. Ugeskr Laeger. 2017. PMID: 29053095 Free article. Review. Danish.
The Danish parliament has decided to establish a four-year pilot scheme for medical treatment with cannabis. We increasingly experience requests from parents for medical treatment with cannabis of children and have the impression that a growing number of parents tre …
The Danish parliament has decided to establish a four-year pilot scheme for medical treatment with cannabis. We increasingly experien …
A Green Microwave-Assisted Extraction of Cannabis sativa L. Extract and Its Cytotoxic Activity Against Cancer Cells.
Suttithumsatid W, Sukketsiri W, Panichayupakaranant P. Suttithumsatid W, et al. Turk J Pharm Sci. 2025 Mar 7;22(1):64-70. doi: 10.4274/tjps.galenos.2025.33490. Turk J Pharm Sci. 2025. PMID: 40052396 Free PMC article.
OBJECTIVES: This study aimed to explore the use of D-limonene and some vegetable oils with different amounts of saturated and unsaturated fatty acids as alternative green solvents for microwave-assisted extraction (MAE) of cannabis (Cannabis sativa L.). A standardiz …
OBJECTIVES: This study aimed to explore the use of D-limonene and some vegetable oils with different amounts of saturated and unsaturated fa …
Cannabinoids for SARS-CoV-2 and is there evidence of their therapeutic efficacy?
Onay A, Ertaş A, Süzerer V, Yener İ, Yilmaz MA, Ayaz-Tilkat E, Ekinci R, Bozhan N, Irtegün-Kandemir S. Onay A, et al. Turk J Biol. 2021 Aug 30;45(4):570-587. doi: 10.3906/biy-2105-73. eCollection 2021. Turk J Biol. 2021. PMID: 34803455 Free PMC article.
Cannabinoids, the main constituents of cannabis (Cannabis sativa L.), are therapeutic compounds that have received international attention in the health field due to their therapeutic properties. ...Indeed, cannabinoid-type compounds, and in particular cannabidiol ( …
Cannabinoids, the main constituents of cannabis (Cannabis sativa L.), are therapeutic compounds that have received internation …
Intraperitoneal delivery of cannabidiol (CBD) and Δ9-tetrahydocannabinol (THC) promotes papillomavirus infections in athymic nude mice.
Brendle SA, Li J, Sun D, Zhu J, Henderson-Redmond AN, Morgan DJ, Balogh KK, Covington D, Shearer DA, Hu J. Brendle SA, et al. Tumour Virus Res. 2025 Jun;19:200307. doi: 10.1016/j.tvr.2024.200307. Epub 2024 Dec 16. Tumour Virus Res. 2025. PMID: 39694192 Free PMC article.
These doses are comparable to what is estimated for human conventional cannabis consumption. All mice were infected with MmuPV1 in the oral cavity at week 4 post-ip delivery of CBD, THC, or a combination of THC and CBD (T + C). ...
These doses are comparable to what is estimated for human conventional cannabis consumption. All mice were infected with MmuPV1 in th …
Cannabis smoke can be a major risk factor for early-age laryngeal cancer--a molecular signaling-based approach.
Bhattacharyya S, Mandal S, Banerjee S, Mandal GK, Bhowmick AK, Murmu N. Bhattacharyya S, et al. Tumour Biol. 2015 Aug;36(8):6029-36. doi: 10.1007/s13277-015-3279-4. Epub 2015 Mar 4. Tumour Biol. 2015. PMID: 25736926 Free article.
This study investigated the expression pattern of key proteins linked to the EGFR pathway in laryngeal carcinoma patients with a history of cannabis smoking. We selected 83 male glottic cancer patients, aged between 45 to 75 years with three distinct populations-non …
This study investigated the expression pattern of key proteins linked to the EGFR pathway in laryngeal carcinoma patients with a history of …
Cannabinoids use in adolescents and young adults with cancer: a single-center survey.
Podda M, Pagani Bagliacca E, Sironi G, Veneroni L, Silva M, Angi M, Massimino M, Ferrari A, Clerici CA. Podda M, et al. Tumori. 2020 Aug;106(4):281-285. doi: 10.1177/0300891620912022. Epub 2020 Mar 17. Tumori. 2020. PMID: 32178596
OBJECTIVE: To present an investigation into the intake of cannabinoids in a population of adolescents and young adults with cancer. METHODS: Sixty-six patients took part in the research: 27 reported having used cannabinoids, 21 before diagnosis; among the latter, 10 increa …
OBJECTIVE: To present an investigation into the intake of cannabinoids in a population of adolescents and young adults with cancer. M …
Correction: Medicinal Cannabis (MedCan 3): a randomised, multicentre, double-blind, placebo-controlled trial to assess THC/CBD (1:20) to relieve symptom burden in patients with cancer-a study protocol for a randomised controlled trial.
Gurgenci T, Hardy J, Huggett G, Foster K, Pelecanos A, Greer R, Philip J, Haywood A, Mendis R, Yates P, Good P. Gurgenci T, et al. Trials. 2024 May 30;25(1):350. doi: 10.1186/s13063-024-08195-6. Trials. 2024. PMID: 38816764 Free PMC article. No abstract available.
Prevention of persistent pain with lidocaine infusions in breast cancer surgery (PLAN): study protocol for a multicenter randomized controlled trial.
Khan JS, Gilron I, Devereaux PJ, Clarke H, Ayach N, Tomlinson G, Quan ML, Ladha KS, Choi S, Munro A, Brull R, Lim DW, Avramescu S, Richebé P, Hodgson N, Paul J, McIsaac DI, Derzi S, Zbitnew GL, Easson AM, Siddiqui NT, Miles SJ, Karkouti K; PLAN Trial Investigators. Khan JS, et al. Trials. 2024 May 22;25(1):337. doi: 10.1186/s13063-024-08151-4. Trials. 2024. PMID: 38773653 Free PMC article.
We aim to determine the definitive effects of this intervention in patients undergoing breast cancer surgery. METHODS: PLAN will be a multicenter, parallel-group, blinded, 1:1 randomized, placebo-controlled trial of 1,602 patients undergoing breast cancer surgery. . …
We aim to determine the definitive effects of this intervention in patients undergoing breast cancer surgery. METHODS: PLAN will be a …
Medicinal Cannabis (MedCan 3): a randomised, multicentre, double-blind, placebo-controlled trial to assess THC/CBD (1:20) to relieve symptom burden in patients with cancer-a study protocol for a randomised controlled trial.
Gurgenci T, Hardy J, Huggett G, Foster K, Pelecanos A, Greer R, Philip J, Haywood A, Mendis R, Yates P, Good P. Gurgenci T, et al. Trials. 2024 May 1;25(1):293. doi: 10.1186/s13063-024-08091-z. Trials. 2024. PMID: 38693590 Free PMC article.
BACKGROUND: Distressing symptoms are common in advanced cancer. Medicinal cannabinoids are commonly prescribed for a variety of symptoms. There is little evidence to support their use for most indications in palliative care. ...DISCUSSION: MedCan-3 is a high-quality, adequ …
BACKGROUND: Distressing symptoms are common in advanced cancer. Medicinal cannabinoids are commonly prescribed for a variety of sympt …
A small clinical trial of vaporized cannabis for PTSD: suggestive results and directions for future study.
Walsh Z, Mitchell I, Crosby K, St Pierre M, DeClerck D, Ong K, Lucas P. Walsh Z, et al. Trials. 2023 Sep 9;24(1):578. doi: 10.1186/s13063-023-07543-2. Trials. 2023. PMID: 37689680 Free PMC article. Clinical Trial.
The last few decades have seen increasing interest in the use of cannabis for post-traumatic stress disorder (PTSD). Recent attempts to evaluate the clinical efficacy of cannabis for PTSD were inconclusive and generalizability was limited by undesirable features of …
The last few decades have seen increasing interest in the use of cannabis for post-traumatic stress disorder (PTSD). Recent attempts …
Using a qualitative sub-study to inform the design and delivery of randomised controlled trials on medicinal cannabis for symptom relief in patients with advanced cancer.
Olson RE, Smith A, Huggett G, Good P, Dudley M, Hardy J. Olson RE, et al. Trials. 2022 Sep 5;23(1):752. doi: 10.1186/s13063-022-06691-1. Trials. 2022. PMID: 36064621 Free PMC article.
This paper reports on findings from a qualitative sub-study supporting RCTs of medicinal cannabis for symptom burden relief in patients with advanced cancer in one Australian city. METHODS: Semi-structured qualitative interviews were conducted with 48 patients with …
This paper reports on findings from a qualitative sub-study supporting RCTs of medicinal cannabis for symptom burden relief in patien …
Clinical trials with cannabis medicines-guidance for ethics committees, governance officers and researchers to streamline ethics applications and ensuring patient safety: considerations from the Australian experience.
Martin JH, Hill C, Walsh A, Efron D, Taylor K, Kennedy M, Galettis R, Lightfoot P, Hanson J, Irving H, Agar M, Lacey J. Martin JH, et al. Trials. 2020 Nov 17;21(1):932. doi: 10.1186/s13063-020-04862-6. Trials. 2020. PMID: 33203469 Free PMC article.
With cannabis medicines now obtaining legal status in many international jurisdictions (generally on the authorisation of a medical professional), a rapid increase in consumer demand for access to cannabis as a therapeutic option in the treatment and management of a …
With cannabis medicines now obtaining legal status in many international jurisdictions (generally on the authorisation of a medical p …
Oral medicinal cannabinoids to relieve symptom burden in the palliative care of patients with advanced cancer: a double-blind, placebo-controlled, randomised clinical trial of efficacy and safety of 1:1 delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD).
Hardy J, Haywood A, Gogna G, Martin J, Yates P, Greer R, Good P. Hardy J, et al. Trials. 2020 Jul 6;21(1):611. doi: 10.1186/s13063-020-04541-6. Trials. 2020. PMID: 32631447 Free PMC article.
BACKGROUND: Despite improvements in medical care, patients with advanced cancer still experience substantial symptom distress. There is increasing interest in the use of medicinal cannabinoids but little high-quality evidence to guide clinicians. ...DISCUSSION: This will b …
BACKGROUND: Despite improvements in medical care, patients with advanced cancer still experience substantial symptom distress. There …
Cannabidiol Claims and Misconceptions.
Russo EB. Russo EB. Trends Pharmacol Sci. 2017 Mar;38(3):198-201. doi: 10.1016/j.tips.2016.12.004. Epub 2017 Jan 12. Trends Pharmacol Sci. 2017. PMID: 28089139
Once a widely ignored phytocannabinoid, cannabidiol now attracts great therapeutic interest, especially in epilepsy and cancer. As with many rising trends, various myths and misconceptions have accompanied this heightened public interest and intrigue. ...
Once a widely ignored phytocannabinoid, cannabidiol now attracts great therapeutic interest, especially in epilepsy and cancer. As wi …
Non-psychotropic plant cannabinoids: new therapeutic opportunities from an ancient herb.
Izzo AA, Borrelli F, Capasso R, Di Marzo V, Mechoulam R. Izzo AA, et al. Trends Pharmacol Sci. 2009 Oct;30(10):515-27. doi: 10.1016/j.tips.2009.07.006. Epub 2009 Sep 2. Trends Pharmacol Sci. 2009. PMID: 19729208 Review.
The well-known psychotropic effects of Delta(9)-tetrahydrocannabinol, which are mediated by activation of brain CB(1) receptors, have greatly limited its clinical use. However, the plant Cannabis contains many cannabinoids with weak or no psychoactivity that, therapeutical …
The well-known psychotropic effects of Delta(9)-tetrahydrocannabinol, which are mediated by activation of brain CB(1) receptors, have greatl …
A Narrative Review of the Lesser Known Medications for Treatment of Restless Legs Syndrome and Pathogenetic Implications for Their Use.
Yeh PG, Spruyt K, DelRosso LM, Walters AS. Yeh PG, et al. Tremor Other Hyperkinet Mov (N Y). 2023 Mar 2;13:7. doi: 10.5334/tohm.739. eCollection 2023. Tremor Other Hyperkinet Mov (N Y). 2023. PMID: 36873914 Free PMC article. Review.
RESULTS: Alternative pharmacological agents include clonidine which reduces adrenergic transmission, adenosinergic agents such as dipyridamole, glutamate AMPA receptor blocking agents such as perampanel, glutamate NMDA receptor blocking agents such as amantadine and ketamine, var …
RESULTS: Alternative pharmacological agents include clonidine which reduces adrenergic transmission, adenosinergic agents such as dipyridamo …
Association of cannabis with glutamatergic levels in patients with early psychosis: Evidence for altered volume striatal glutamate relationships in patients with a history of cannabis use in early psychosis.
Sami M, Worker A, Colizzi M, Annibale L, Das D, Kelbrick M, Eranti S, Collier T, Onyejiaka C, O'Neill A, Lythgoe D, McGuire P, Williams SCR, Kempton MJ, Bhattacharyya S; Collaborators. Sami M, et al. Transl Psychiatry. 2020 Apr 21;10(1):111. doi: 10.1038/s41398-020-0790-1. Transl Psychiatry. 2020. PMID: 32317625 Free PMC article.
We sought to see if glutamatergic indices are altered between early psychosis patients with and without a history of cannabis use and characterise the relationship to grey matter. 92 participants were scanned: Early Psychosis with a history of cannabis use (EPC = 29 …
We sought to see if glutamatergic indices are altered between early psychosis patients with and without a history of cannabis use and …
Optimization of seizure prevention by cannabidiol (CBD).
Bhandari B, Naeini SE, Rezaee S, Rogers HM, Khodadadi H, Bosomtwi A, Seyyedi M, MacKinnon NJ, Dhandapani KM, Salles ÉL, Hess DC, Yu JC, Moore-Hill D, Vale FL, Wang LP, Baban B. Bhandari B, et al. Transl Neurosci. 2025 Mar 28;16(1):20220362. doi: 10.1515/tnsci-2022-0362. eCollection 2025 Jan 1. Transl Neurosci. 2025. PMID: 40177581 Free PMC article.
Based on its anti-seizure efficacy, the first cannabis derived pharmaceutical grade CBD-based medication was approved in the USA in 2018 for the treatment of seizures in patients 2 years and older. ...
Based on its anti-seizure efficacy, the first cannabis derived pharmaceutical grade CBD-based medication was approved in the USA in 2 …
Cannabis: A Toxin-Producing Plant with Potential Therapeutic Uses.
Breijyeh Z, Jubeh B, Bufo SA, Karaman R, Scrano L. Breijyeh Z, et al. Toxins (Basel). 2021 Feb 5;13(2):117. doi: 10.3390/toxins13020117. Toxins (Basel). 2021. PMID: 33562446 Free PMC article. Review.
Medical cannabis varies from recreational cannabis in the chemical content of THC and cannabidiol (CBD), modes of administration, and safety. ...This review focuses on the potential therapeutic effects of cannabis and cannabinoids, as well as the acute and ch …
Medical cannabis varies from recreational cannabis in the chemical content of THC and cannabidiol (CBD), modes of administrati …
Neuronal and Astrocytic Morphological Alterations Driven by Prolonged Exposure with Δ9-Tetrahydrocannabinol but Not Cannabidiol.
Landucci E, Mazzantini C, Lana D, Giovannini MG, Pellegrini-Giampietro DE. Landucci E, et al. Toxics. 2022 Jan 21;10(2):48. doi: 10.3390/toxics10020048. Toxics. 2022. PMID: 35202235 Free PMC article.
Cannabis derivatives are largely used in the general population for recreational and medical purposes, with the highest prevalence among adolescents, but chronic use and abuse has raised medical concerns. ...
Cannabis derivatives are largely used in the general population for recreational and medical purposes, with the highest prevalence am …
delta(9)-THC modulation of fatty acid 2-hydroxylase (FA2H) gene expression: possible involvement of induced levels of PPARalpha in MDA-MB-231 breast cancer cells.
Takeda S, Ikeda E, Su S, Harada M, Okazaki H, Yoshioka Y, Nishimura H, Ishii H, Kakizoe K, Taniguchi A, Tokuyasu M, Himeno T, Watanabe K, Omiecinski CJ, Aramaki H. Takeda S, et al. Toxicology. 2014 Dec 4;326:18-24. doi: 10.1016/j.tox.2014.09.011. Epub 2014 Oct 5. Toxicology. 2014. PMID: 25291031 Free PMC article.
We recently reported that delta(9)-tetrahydrocannabinol (delta(9)-THC), a major cannabinoid component in Cannabis Sativa (marijuana), significantly stimulated the expression of fatty acid 2-hydroxylase (FA2H) in human breast cancer MDA-MB-231 cells. ...
We recently reported that delta(9)-tetrahydrocannabinol (delta(9)-THC), a major cannabinoid component in Cannabis Sativa (marijuana), …
Modulation of Delta9-tetrahydrocannabinol-induced MCF-7 breast cancer cell growth by cyclooxygenase and aromatase.
Takeda S, Yamamoto I, Watanabe K. Takeda S, et al. Toxicology. 2009 May 2;259(1-2):25-32. doi: 10.1016/j.tox.2009.01.024. Epub 2009 Feb 4. Toxicology. 2009. PMID: 19428940
Delta(9)-Tetrahydrocannabinol (Delta(9)-THC), a major constituent of marijuana, has been shown to stimulate the growth of MCF-7 breast cancer cells through cannabinoid receptor-independent signaling [Takeda, S., Yamaori, S., Motoya, E., Matsunaga, T., Kimura, T., Yamamoto, …
Delta(9)-Tetrahydrocannabinol (Delta(9)-THC), a major constituent of marijuana, has been shown to stimulate the growth of MCF-7 breast ca …
Paternal Cannabis Exposure Prior to Mating, but Not delta9-Tetrahydrocannabinol, Elicits Deficits in Dopaminergic Synaptic Activity in the Offspring.
Slotkin TA, Levin ED, Seidler FJ. Slotkin TA, et al. Toxicol Sci. 2021 Nov 24;184(2):252-264. doi: 10.1093/toxsci/kfab117. Toxicol Sci. 2021. PMID: 34590702 Free PMC article.
We administered cannabis extract to male rats prior to mating, with two different 28-day exposures, one where there was a 56-day interval between the end of exposure and mating ("Early Cannabis"), and one just prior to mating ("Late Cannabis"); the extract de …
We administered cannabis extract to male rats prior to mating, with two different 28-day exposures, one where there was a 56-day inte …
Antiproliferative effects of cadmium sulfide nanoparticles obtained from walnut shells by green synthesis method on SH-SY5Y cell line.
Yeni Y, Nadaroglu H, Ertugrul MS, Hacimuftuoglu A, Alayli A. Yeni Y, et al. Toxicol Rep. 2024 Nov 19;13:101818. doi: 10.1016/j.toxrep.2024.101818. eCollection 2024 Dec. Toxicol Rep. 2024. PMID: 39649381 Free PMC article.
Nanoparticles are attracting attention for their potential therapeutic applications, particularly in cancer therapy, underscoring their importance in medicine. Cadmium sulfide nanoparticles, known for their robust catalytic and optical properties, are classified as chalcog …
Nanoparticles are attracting attention for their potential therapeutic applications, particularly in cancer therapy, underscoring the …
Chemical and biological studies of beta-carotene after exposure to Cannabis sativa smoke.
do Monte DS, Bezerra Tenório JA, Bastos IVGA, de S Mendonça F, Neto JE, da Silva TG, Ramos CS. do Monte DS, et al. Toxicol Rep. 2016 Jun 3;3:516-522. doi: 10.1016/j.toxrep.2016.06.001. eCollection 2016. Toxicol Rep. 2016. PMID: 28959575 Free PMC article.
Considering the increase in consumption of Cannabis sativa and the use of the compound beta-carotene (BC) as supplement, we investigated potential changes in the chemical and biological proprieties of BC after exposure to C. sativa smoke (CSS). ...These are found in higher …
Considering the increase in consumption of Cannabis sativa and the use of the compound beta-carotene (BC) as supplement, we investiga …
Effects of prenatal exposure to THC on hippocampal neural development in offspring.
Peng H, Li H, Wei Y, Zhang R, Chang X, Meng L, Wang K, He Q, Duan T. Peng H, et al. Toxicol Lett. 2023 Feb 1;374:48-56. doi: 10.1016/j.toxlet.2022.12.007. Epub 2022 Dec 15. Toxicol Lett. 2023. PMID: 36529297 Free article.
Cannabis use is a worldwide issue with the development of legalization. Prenatal exposure to delta9-tetrahydrocannabinol (THC), the main psychoactive component of cannabis, is related to affect fetal nervous system development. ...
Cannabis use is a worldwide issue with the development of legalization. Prenatal exposure to delta9-tetrahydrocannabinol (THC), the m …
Cannabidiolic acid, a major cannabinoid in fiber-type cannabis, is an inhibitor of MDA-MB-231 breast cancer cell migration.
Takeda S, Okajima S, Miyoshi H, Yoshida K, Okamoto Y, Okada T, Amamoto T, Watanabe K, Omiecinski CJ, Aramaki H. Takeda S, et al. Toxicol Lett. 2012 Nov 15;214(3):314-9. doi: 10.1016/j.toxlet.2012.08.029. Epub 2012 Sep 8. Toxicol Lett. 2012. PMID: 22963825 Free PMC article.
Cannabidiol (CBD), a major non-psychotropic constituent of fiber-type cannabis plant, has been reported to possess diverse biological activities, including anti-proliferative effect on cancer cells. ...It is established that activation of the RhoA signaling pathway …
Cannabidiol (CBD), a major non-psychotropic constituent of fiber-type cannabis plant, has been reported to possess diverse biological …
Cannabinoids and standardized cannabis extracts inhibit migration, invasion, and induce apoptosis in MCF-7 cells through FAK/MAPK/Akt/NF-kappaB signaling.
Suttithumsatid W, Sukketsiri W, Panichayupakaranant P. Suttithumsatid W, et al. Toxicol In Vitro. 2023 Dec;93:105667. doi: 10.1016/j.tiv.2023.105667. Epub 2023 Aug 23. Toxicol In Vitro. 2023. PMID: 37625625
BACKGROUND: Breast cancer is the highest incidence of all types of cancer in women, and the cancer metastasis process accounts for a majority of cancer deaths. Two major cannabinoids, delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD), from Ca …
BACKGROUND: Breast cancer is the highest incidence of all types of cancer in women, and the cancer metastasis process a …
The neuroprotection of cannabidiol against MPP⁺-induced toxicity in PC12 cells involves trkA receptors, upregulation of axonal and synaptic proteins, neuritogenesis, and might be relevant to Parkinson's disease.
Santos NA, Martins NM, Sisti FM, Fernandes LS, Ferreira RS, Queiroz RH, Santos AC. Santos NA, et al. Toxicol In Vitro. 2015 Dec 25;30(1 Pt B):231-40. doi: 10.1016/j.tiv.2015.11.004. Epub 2015 Nov 7. Toxicol In Vitro. 2015. PMID: 26556726 Free article.
Cannabidiol (CBD) is a non-psychoactive constituent of Cannabis sativa with potential to treat neurodegenerative diseases. Its neuroprotection has been mainly associated with anti-inflammatory and antioxidant events; however, other mechanisms might be involved. ...
Cannabidiol (CBD) is a non-psychoactive constituent of Cannabis sativa with potential to treat neurodegenerative diseases. Its neurop …
Investigation of the in vitro toxicological properties of the synthetic cannabimimetic drug CP-47,497-C8.
Koller VJ, Auwärter V, Grummt T, Moosmann B, Mišík M, Knasmüller S. Koller VJ, et al. Toxicol Appl Pharmacol. 2014 Jun 1;277(2):164-71. doi: 10.1016/j.taap.2014.03.014. Epub 2014 Mar 28. Toxicol Appl Pharmacol. 2014. PMID: 24686252
Cannabicyclohexanol (CP-47,497-C8) is a representative of a group of cannabimimetic cyclohexylphenols which is added to herbal mixtures as a cannabis substitute since 2008. Although in the beginning CP-47,497-C8 was the main ingredient of "Spice" and similar products, it w …
Cannabicyclohexanol (CP-47,497-C8) is a representative of a group of cannabimimetic cyclohexylphenols which is added to herbal mixtures as a …
Protective Behavioural Mechanisms Against Cannabis Use Among Adolescents in Cannabis-Growing Settings of South Africa: Insights Into Adolescent Cannabis Use Prevention.
Manu E, Douglas M, Ntsaba MJ, Makaula B, Tarkang EE. Manu E, et al. Tob Use Insights. 2022 Dec 14;15:1179173X221146040. doi: 10.1177/1179173X221146040. eCollection 2022. Tob Use Insights. 2022. PMID: 36544696 Free PMC article.
We aimed to explore the behavioural protective mechanisms against cannabis use among adolescents living in South African illicit cannabis-growing communities, based on the Self Determination Theory (SDT). ...On the other hand, the concept of Ukuphoxa (preservation o …
We aimed to explore the behavioural protective mechanisms against cannabis use among adolescents living in South African illicit c …
Reactions to vaping cessation messaging and strategies among US young adults who use e-cigarettes.
Romm KF, Le D, Abroms LC, Berg CJ. Romm KF, et al. Tob Prev Cessat. 2024 Apr 11;10. doi: 10.18332/tpc/186271. eCollection 2024. Tob Prev Cessat. 2024. PMID: 38606059 Free PMC article.
We examined: 1) perceived challenges to quitting e-cigarettes; 2) perceived impact of intervention messages targeting motivation and confidence, and their associations with quitting importance and confidence; and 3) poly-use with cigarettes and/or cannabis in relation to p …
We examined: 1) perceived challenges to quitting e-cigarettes; 2) perceived impact of intervention messages targeting motivation and confide …
Exploring young adults' e-cigarette use behavior during COVID-19.
Clausen M, Romm KF, Berg CJ, Ciceron AC, Fuss C, Bennett B, Le D. Clausen M, et al. Tob Prev Cessat. 2022 Dec 15;8:45. doi: 10.18332/tpc/155332. eCollection 2022. Tob Prev Cessat. 2022. PMID: 36568488 Free PMC article.
Participants were drawn from 6 metropolitan statistical areas with varied tobacco and cannabis legislative contexts. RESULTS: Among survey participants, 44.4% also smoked cigarettes, 54.0% other tobacco products, and 60.1% used cannabis. ...
Participants were drawn from 6 metropolitan statistical areas with varied tobacco and cannabis legislative contexts. RESULTS: Among s …
Support for pictorial health warning labels on cigarette packages in the United States among adults who currently smoke or quit smoking: Findings from the ITC US Smoking and Vaping Surveys.
Gravely S, Meng G, Hammond D, Driezen P, Thrasher JF, Fong GT, Craig LV, Chung-Hall J, Quah ACK, Ouimet J, Bansal-Travers M, Cummings KM. Gravely S, et al. Tob Induc Dis. 2023 Jun 23;21:84. doi: 10.18332/tid/166001. eCollection 2023. Tob Induc Dis. 2023. PMID: 37360042 Free PMC article.
Assessing use of inhalable nicotine products within complex markets: the dilemma of heated tobacco products.
Miller CR, Xu SS, Smith DM, Sutanto E, Goniewicz ML, Quah ACK, Fong GT. Miller CR, et al. Tob Control. 2023 Dec 13;33(1):103-109. doi: 10.1136/tobaccocontrol-2021-057081. Tob Control. 2023. PMID: 35680384 Free PMC article.
This paper raises concerns of potential measurement error for electronic inhalable product use in surveys due to similarities in product design between NVPs and HTPs, as well as changing trends in cannabis administration. We identify several strategies for addressing this …
This paper raises concerns of potential measurement error for electronic inhalable product use in surveys due to similarities in product des …
'I'm killing myself, but I'm saving the planet': rolling tobacco smokers' perceptions of rolling papers.
Moodie C, O'Donnell R. Moodie C, et al. Tob Control. 2022 May;31(3):479-482. doi: 10.1136/tobaccocontrol-2020-056103. Epub 2020 Nov 23. Tob Control. 2022. PMID: 33229464
Participants often associated papers with particular users, with prerolled cones and some flavoured papers thought to be used by cannabis smokers or younger people and those just starting to smoke. In terms of harm perceptions, natural papers were viewed as a healthier cho …
Participants often associated papers with particular users, with prerolled cones and some flavoured papers thought to be used by cannabis …
Have e-cigarettes renormalised or displaced youth smoking? Results of a segmented regression analysis of repeated cross sectional survey data in England, Scotland and Wales.
Hallingberg B, Maynard OM, Bauld L, Brown R, Gray L, Lowthian E, MacKintosh AM, Moore L, Munafo MR, Moore G. Hallingberg B, et al. Tob Control. 2020 Mar;29(2):207-216. doi: 10.1136/tobaccocontrol-2018-054584. Epub 2019 Apr 1. Tob Control. 2020. PMID: 30936390 Free PMC article.
Secondary outcomes were attitudes towards smoking. Tertiary outcomes were ever use of cannabis and alcohol. RESULTS: In final models, no significant change was detected in the pre-existing trend for ever smoking (OR 1.01, CI 0.99 to 1.03). There was a marginally significan …
Secondary outcomes were attitudes towards smoking. Tertiary outcomes were ever use of cannabis and alcohol. RESULTS: In final models, …
Prospective study of e-cigarette use and respiratory symptoms in adolescents and young adults.
Tackett AP, Urman R, Barrington-Trimis J, Liu F, Hong H, Pentz MA, Islam TS, Eckel SP, Rebuli M, Leventhal A, Samet JM, Berhane K, McConnell R. Tackett AP, et al. Thorax. 2024 Jan 18;79(2):163-168. doi: 10.1136/thorax-2022-218670. Thorax. 2024. PMID: 37582630 Free PMC article.
METHODS: Participants completed questionnaires on respiratory symptoms and past 30-day e-cigarette, cigarette and cannabis use in 2014 (wave 1; N=2094; mean age 17.3 years, SD=0.6 years). Follow-up information was collected in 2015 (wave 2; n=1609), 2017 (wave 3; n=1502) a …
METHODS: Participants completed questionnaires on respiratory symptoms and past 30-day e-cigarette, cigarette and cannabis use in 201 …
[Cannabis and the lung - chill or kill?].
Grendelmeier P. Grendelmeier P. Ther Umsch. 2010 Aug;67(8):427-30. doi: 10.1024/0040-5930/a000075. Ther Umsch. 2010. PMID: 20687046 German.
Cannabis is the most widely consumed illicit drug in the western world. Cannabis and tobacco smoke contain a similar mix of irritant and toxic chemicals. Therefore, there are reasons to suspect, that cannabis and tobacco have similar side effects. However, th …
Cannabis is the most widely consumed illicit drug in the western world. Cannabis and tobacco smoke contain a similar mix of ir …
[Desired effects and adverse effects of cannabis use].
Drewe J. Drewe J. Ther Umsch. 2003 Jun;60(6):313-6. doi: 10.1024/0040-5930.60.6.313. Ther Umsch. 2003. PMID: 12848065 German.
Cannabis use can result in relevant impairment of driving ability. The risk is enhanced by concomitant use of alcohol. ...Chronic marijuana smoking is associated with increased toxicity and the risk of cancer of the respiratory tract. There is evidence of disturbanc …
Cannabis use can result in relevant impairment of driving ability. The risk is enhanced by concomitant use of alcohol. ...Chronic mar …
Real World Evidence in Medical Cannabis Research.
Banerjee R, Erridge S, Salazar O, Mangal N, Couch D, Pacchetti B, Sodergren MH. Banerjee R, et al. Ther Innov Regul Sci. 2022 Jan;56(1):8-14. doi: 10.1007/s43441-021-00346-0. Epub 2021 Nov 8. Ther Innov Regul Sci. 2022. PMID: 34748204 Free PMC article.
BACKGROUND: Whilst access to cannabis-based medicinal products (CBMPs) has increased globally subject to relaxation of scheduling laws globally, one of the main barriers to appropriate patient access remains a paucity of high-quality evidence surrounding their clinical eff …
BACKGROUND: Whilst access to cannabis-based medicinal products (CBMPs) has increased globally subject to relaxation of scheduling law …
Variable Delta-9-Tetrahydrocannabinol Pharmacokinetics and Pharmacodynamics After Cannabis Smoking in Regular Users.
Liyanage M, Nikanjam M, Capparelli EV, Suhandynata RT, Fitzgerald RL, Marcotte TD, Grant I, Momper JD. Liyanage M, et al. Ther Drug Monit. 2023 Oct 1;45(5):689-696. doi: 10.1097/FTD.0000000000001104. Epub 2023 May 4. Ther Drug Monit. 2023. PMID: 37199428
BACKGROUND: Despite its federally restricted status, cannabis is widely used medicinally and recreationally. The pharmacokinetics (PK) and central nervous system (CNS) effects of tetrahydrocannabinol (THC), the major psychoactive cannabinoid, are not well understood. The o …
BACKGROUND: Despite its federally restricted status, cannabis is widely used medicinally and recreationally. The pharmacokinetics (PK …
Dronabinol oral solution in the management of anorexia and weight loss in AIDS and cancer.
Badowski ME, Yanful PK. Badowski ME, et al. Ther Clin Risk Manag. 2018 Apr 6;14:643-651. doi: 10.2147/TCRM.S126849. eCollection 2018. Ther Clin Risk Manag. 2018. PMID: 29670357 Free PMC article. Review.
Dronabinol, or delta-9-tetrahydrocannabinol, is a synthetic molecule that closely mimics the action of Cannabis sativa L., a naturally occurring compound activated in the central nervous system by cannabinoid receptors. ...However, there is no approved indication in the se …
Dronabinol, or delta-9-tetrahydrocannabinol, is a synthetic molecule that closely mimics the action of Cannabis sativa L., a naturall …
Cannabinoids in the management of difficult to treat pain.
Russo EB. Russo EB. Ther Clin Risk Manag. 2008 Feb;4(1):245-59. doi: 10.2147/tcrm.s1928. Ther Clin Risk Manag. 2008. PMID: 18728714 Free PMC article.
Other synthetic cannabinoids, such as ajulemic acid, are in development. Crude herbal cannabis remains illegal in most jurisdictions but is also under investigation. Sativex((R)), a cannabis derived oromucosal spray containing equal proportions of THC (partial CB(1) …
Other synthetic cannabinoids, such as ajulemic acid, are in development. Crude herbal cannabis remains illegal in most jurisdictions …
Association between cannabis use and clinical outcomes in patients with solid malignancies receiving immune checkpoint inhibitors.
Hadid T, Biedny A, Mamdani H, Azmi A, Kim S, Jang H, Uprety D, Al Hallak MN, Sukari A. Hadid T, et al. Ther Adv Vaccines Immunother. 2024 Dec 25;12:25151355241309095. doi: 10.1177/25151355241309095. eCollection 2024. Ther Adv Vaccines Immunother. 2024. PMID: 39737331 Free PMC article.
Impact of cannabis use on clinical outcomes in patients with cancer receiving immunotherapy Cannabis (CAN) use has risen significantly over the last few decades. The clinical effect of CAN consumption on cancer patients receiving immunotherapy (IO) rem …
Impact of cannabis use on clinical outcomes in patients with cancer receiving immunotherapy Cannabis (CAN) use has rise …
Clinical outcome analysis of patients with autism spectrum disorder: analysis from the UK Medical Cannabis Registry.
Erridge S, Kerr-Gaffney J, Holvey C, Coomber R, Barros DAR, Bhoskar U, Mwimba G, Praveen K, Symeon C, Sachdeva-Mohan S, Sodergren MH, Rucker JJ. Erridge S, et al. Ther Adv Psychopharmacol. 2022 Sep 20;12:20451253221116240. doi: 10.1177/20451253221116240. eCollection 2022. Ther Adv Psychopharmacol. 2022. PMID: 36159065 Free PMC article.
INTRODUCTION: Cannabis-based medicinal products (CBMPs) have been identified as a promising novel therapeutic for symptoms and comorbidities related to autism spectrum disorder (ASD). ...Objective: This case series aims to assess changes to health-related quality of life a …
INTRODUCTION: Cannabis-based medicinal products (CBMPs) have been identified as a promising novel therapeutic for symptoms and comorb …
Medical cannabis for orthopaedic patients with chronic musculoskeletal pain: does evidence support its use?
Johal H, Vannabouathong C, Chang Y, Zhu M, Bhandari M. Johal H, et al. Ther Adv Musculoskelet Dis. 2020 Jul 2;12:1759720X20937968. doi: 10.1177/1759720X20937968. eCollection 2020. Ther Adv Musculoskelet Dis. 2020. PMID: 32655704 Free PMC article. Review.
This position paper provides a history on the evolution of cannabis, the science behind its therapeutic effects, and review of the evidence and current guideline recommendations on its use as a treatment for patients with chronic, non-cancer musculoskeletal pain. .. …
This position paper provides a history on the evolution of cannabis, the science behind its therapeutic effects, and review of the ev …
Effect of cannabis on oxaliplatin-induced peripheral neuropathy among oncology patients: a retrospective analysis.
Waissengrin B, Mirelman D, Pelles S, Bukstein F, Blumenthal DT, Wolf I, Geva R. Waissengrin B, et al. Ther Adv Med Oncol. 2021 Feb 9;13:1758835921990203. doi: 10.1177/1758835921990203. eCollection 2021. Ther Adv Med Oncol. 2021. PMID: 33613702 Free PMC article.
The patients were divided based upon the exposure to cannabis: prior to oxaliplatin (cannabis-first), cannabis following the initiation of oxaliplatin treatment (oxaliplatin-first), and no exposure (control). ...There was a significant difference in CIPN grad …
The patients were divided based upon the exposure to cannabis: prior to oxaliplatin (cannabis-first), cannabis followin …
Opportunities for cannabis in supportive care in cancer.
Kleckner AS, Kleckner IR, Kamen CS, Tejani MA, Janelsins MC, Morrow GR, Peppone LJ. Kleckner AS, et al. Ther Adv Med Oncol. 2019 Aug 1;11:1758835919866362. doi: 10.1177/1758835919866362. eCollection 2019. Ther Adv Med Oncol. 2019. PMID: 31413731 Free PMC article. Review.
Cannabis has the potential to modulate some of the most common and debilitating symptoms of cancer and its treatments, including nausea and vomiting, loss of appetite, and pain. ...A review was performed using keywords related to cannabis and important sympto …
Cannabis has the potential to modulate some of the most common and debilitating symptoms of cancer and its treatments, includi …
Cannabinoidomics - An analytical approach to understand the effect of medical Cannabis treatment on the endocannabinoid metabolome.
Berman P, Sulimani L, Gelfand A, Amsalem K, Lewitus GM, Meiri D. Berman P, et al. Talanta. 2020 Nov 1;219:121336. doi: 10.1016/j.talanta.2020.121336. Epub 2020 Jul 10. Talanta. 2020. PMID: 32887067 Free article.
The biological effects of Cannabis have been attributed to phytocannabinoid modulation of the endocannabinoid system. ...However, it is not yet understood whether whole Cannabis extracts exert variable effects on the endocannabinoid metabolome, and whether these eff …
The biological effects of Cannabis have been attributed to phytocannabinoid modulation of the endocannabinoid system. ...However, it …
The impact of chiropractic care on prescription opioid use for non-cancer spine pain: protocol for a systematic review and meta-analysis.
Emary PC, Corcoran KL, Coleman BC, Brown AL, Ciraco C, DiDonato J, Wang L, Couban RJ, Sud A, Busse JW. Emary PC, et al. Syst Rev. 2024 Sep 12;13(1):232. doi: 10.1186/s13643-024-02654-6. Syst Rev. 2024. PMID: 39267131 Free PMC article.
BACKGROUND: In recent studies, receipt of chiropractic care has been associated with lower odds of receiving prescription opioids and, among those already prescribed, reduced doses of opioids among patients with non-cancer spine pain. These findings suggest that access to …
BACKGROUND: In recent studies, receipt of chiropractic care has been associated with lower odds of receiving prescription opioids and, among …
The effect of medical cannabis on cognitive functions: a systematic review.
Wieghorst A, Roessler KK, Hendricks O, Andersen TE. Wieghorst A, et al. Syst Rev. 2022 Oct 3;11(1):210. doi: 10.1186/s13643-022-02073-5. Syst Rev. 2022. PMID: 36192811 Free PMC article.
BACKGROUND: Cannabis-based medicines are widely used in the treatment of a number of medical conditions. ...FINDINGS: Twenty-three studies were included, comprising a total of N = 917. Eight studies used Sativex as the cannabis-based medicine two used Epidiolex, two …
BACKGROUND: Cannabis-based medicines are widely used in the treatment of a number of medical conditions. ...FINDINGS: Twenty-three st …
Medical cannabis for the reduction of opioid dosage in the treatment of non-cancer chronic pain: a systematic review.
Okusanya BO, Asaolu IO, Ehiri JE, Kimaru LJ, Okechukwu A, Rosales C. Okusanya BO, et al. Syst Rev. 2020 Jul 28;9(1):167. doi: 10.1186/s13643-020-01425-3. Syst Rev. 2020. PMID: 32723354 Free PMC article.
BACKGROUND: Medical cannabis (MC) is currently being used as an adjunct to opiates given its analgesic effects and potential to reduce opiate addiction. ...CONCLUSIONS: While this review indicated the likelihood of reducing opioid dosage when used in combination with MC, w …
BACKGROUND: Medical cannabis (MC) is currently being used as an adjunct to opiates given its analgesic effects and potential to reduc …
Benefits and harms of medical cannabis: a scoping review of systematic reviews.
Pratt M, Stevens A, Thuku M, Butler C, Skidmore B, Wieland LS, Clemons M, Kanji S, Hutton B. Pratt M, et al. Syst Rev. 2019 Dec 10;8(1):320. doi: 10.1186/s13643-019-1243-x. Syst Rev. 2019. PMID: 31823819 Free PMC article.
BACKGROUND: There has been increased interest in the role of cannabis for treating medical conditions. The availability of different cannabis-based products can make the side effects of exposure unpredictable. ...Adverse effects were reported in most reviews compari …
BACKGROUND: There has been increased interest in the role of cannabis for treating medical conditions. The availability of different …
Healthcare provider knowledge, attitudes, beliefs, and practices surrounding the prescription of opioids for chronic non-cancer pain in North America: protocol for a mixed-method systematic review.
Rash JA, Buckley N, Busse JW, Campbell TS, Corace K, Cooper L, Flusk D, Iorio A, Lavoie KL, Poulin PA, Skidmore B. Rash JA, et al. Syst Rev. 2018 Nov 13;7(1):189. doi: 10.1186/s13643-018-0858-7. Syst Rev. 2018. PMID: 30424800 Free PMC article.
CPGs have been developed to support the safe and effective prescription of opioid medication for the management of chronic non-cancer pain. The extent of physician uptake and adherence to such guidelines is not yet well understood. The purpose of this review is to synthesi …
CPGs have been developed to support the safe and effective prescription of opioid medication for the management of chronic non-cancer …
Trends in cannabis use among those with and without a cancer diagnosis according to state-level cannabis policy: findings from the PATH Study, Waves 1-5 (2013-2019).
Martin CD, Rivard C, Kasza K, Case AA, Hansen E, Goniewicz ML, O'Connor RJ, Hyland A, Smith DM. Martin CD, et al. Support Care Cancer. 2025 Jun 9;33(7):560. doi: 10.1007/s00520-025-09617-0. Support Care Cancer. 2025. PMID: 40490566
PURPOSE: Individual states have implemented legal cannabis policies. Individuals with a cancer diagnosis increasingly consume cannabis. It is uncertain whether state-level cannabis policies are differentially associated with trends in cannabis u …
PURPOSE: Individual states have implemented legal cannabis policies. Individuals with a cancer diagnosis increasingly consume …
The impact of cannabis on immune checkpoint inhibitor therapy: a systematic review of immunomodulatory effects of cannabis in patients with and without cancer.
Behling-Hess C, Simonson G, Salz T, Fleege N, Zylla D. Behling-Hess C, et al. Support Care Cancer. 2025 Feb 8;33(3):166. doi: 10.1007/s00520-025-09218-x. Support Care Cancer. 2025. PMID: 39921765 Review.
PURPOSE: Cannabis is commonly used among patients with cancer for palliative benefit. As the use of immune checkpoint inhibitors (ICIs) for cancer therapy increases, there is concern about potential interactions between ICIs and cannabis. ...The goal o …
PURPOSE: Cannabis is commonly used among patients with cancer for palliative benefit. As the use of immune checkpoint inhibito …
Evaluating racial disparities in cancer patient-provider communication about cannabis in a state without a legal cannabis marketplace.
Wedel AV, Walters KJ, Tomko RL, Rojewski AM, McClure EA. Wedel AV, et al. Support Care Cancer. 2025 Jan 8;33(2):78. doi: 10.1007/s00520-024-09131-9. Support Care Cancer. 2025. PMID: 39775254 Free PMC article.
PURPOSE: Cancer survivors in a state with no legal access to cannabis may be hesitant to discuss their cannabis use with providers, particularly in light of legal consequences which disproportionately affect certain racial groups. ...CONCLUSIONS: Results high …
PURPOSE: Cancer survivors in a state with no legal access to cannabis may be hesitant to discuss their cannabis use wit …
Adverse events associated with the use of cannabis-based products in people living with cancer: a systematic scoping review.
Cheah I, Hunter J, Gelissen I, Chan WJ, Harnett JE. Cheah I, et al. Support Care Cancer. 2024 Dec 18;33(1):40. doi: 10.1007/s00520-024-09087-w. Support Care Cancer. 2024. PMID: 39694905 Free PMC article.
PURPOSE: To summarise the extent and type of evidence in relation to adverse events (AEs) associated with the use of cannabis-based products (CBP) in people living with cancer. METHODS: The Joanna Briggs Institute (JBI) methodology for scoping reviews was applied. . …
PURPOSE: To summarise the extent and type of evidence in relation to adverse events (AEs) associated with the use of cannabis-based p …
Real-world patient experience with medicinal cannabis use for symptom management in an Australian advanced cancer setting: a mixed method, cohort study using the theory of planned behaviour framework.
Ong JA, Lo UC, Musa H, Li J, Gaon J, Lacey J, Cheung JMY, Soriano M. Ong JA, et al. Support Care Cancer. 2024 Nov 15;32(12):795. doi: 10.1007/s00520-024-09013-0. Support Care Cancer. 2024. PMID: 39546029 Free PMC article.
METHODS: Demographic and quantitative data related to MC usage were extracted from medical records for patients prescribed MC at a single cancer centre in metropolitan Sydney. Qualitative data was generated from semi-structured interviews. ...
METHODS: Demographic and quantitative data related to MC usage were extracted from medical records for patients prescribed MC at a single …
Stigma, risks, and benefits of medicinal cannabis use among Australians with cancer.
Morris JN, Loyer J, Blunt J. Morris JN, et al. Support Care Cancer. 2024 Mar 27;32(4):252. doi: 10.1007/s00520-024-08439-w. Support Care Cancer. 2024. PMID: 38532234
PURPOSE: People with cancer who use medicinal cannabis do so despite risks associated with limited clinical evidence, legalities, and stigma. ...Cannabis was used to treat a variety of cancer-related symptoms such as pain, poor sleep, and low mood. ...
PURPOSE: People with cancer who use medicinal cannabis do so despite risks associated with limited clinical evidence, legaliti …
Self-reported knowledge of tetrahydrocannabinol and cannabidiol concentration in cannabis products among cancer patients and survivors.
Goulette M, Schlienz NJ, Case AA, Hansen E, Rivard C, Ashare RL, Goniewicz ML, Bansal-Travers M, Hyland A, Smith DM. Goulette M, et al. Support Care Cancer. 2024 Mar 5;32(4):210. doi: 10.1007/s00520-024-08374-w. Support Care Cancer. 2024. PMID: 38443674 Free PMC article.
PURPOSE: Cannabis use may introduce risks and/or benefits among people living with cancer, depending on product type, composition, and nature of its use. ...METHODS: People living with cancer who consumed cannabis since their diagnosis (n = 343) comple …
PURPOSE: Cannabis use may introduce risks and/or benefits among people living with cancer, depending on product type, composit …
Current cannabis use and pain management among US cancer patients.
Krok-Schoen JL, Plascak JJ, Newton AM, Strassels SA, Adib A, Adley NC, Hays JL, Wagener TL, Stevens EE, Brasky TM. Krok-Schoen JL, et al. Support Care Cancer. 2024 Jan 18;32(2):111. doi: 10.1007/s00520-024-08321-9. Support Care Cancer. 2024. PMID: 38236449 Free PMC article.
While pain is a primary motivation to use cannabis in cancer, the magnitude of its association with cannabis use remains understudied. ...CONCLUSIONS: Use of cannabis among cancer patients may be related to their treatment and is positively asso …
While pain is a primary motivation to use cannabis in cancer, the magnitude of its association with cannabis use remain …
Exploring potential anti-inflammatory effects of medicinal cannabis.
Gurgenci T, Kijanka G, Greer R, Huggett G, Good P, Moniruzzaman M, Hardy J. Gurgenci T, et al. Support Care Cancer. 2023 Oct 14;31(12):629. doi: 10.1007/s00520-023-08069-8. Support Care Cancer. 2023. PMID: 37837446 Free PMC article. Clinical Trial.
PURPOSE: Inflammation is thought to play a key role in malignant disease and may play a significant part in the expression of cancer-related symptoms. Cannabidiol (CBD) is a bioactive compound in cannabis and is reported to have significant anti-inflammatory propert …
PURPOSE: Inflammation is thought to play a key role in malignant disease and may play a significant part in the expression of cancer- …
Knowledge and attitudes towards medicinal cannabis and complementary and integrative medicine (CIM): a survey of healthcare professionals working in a cancer hospital in Australia.
Grant SJ, Gonzalez M, Heller G, Soliman S, Spiegel G, Lacey J. Grant SJ, et al. Support Care Cancer. 2023 Oct 11;31(12):623. doi: 10.1007/s00520-023-08080-z. Support Care Cancer. 2023. PMID: 37819556 Free PMC article.
Most respondents believed that CIM (87.9%) could benefit patients with cancer, and MC could benefit those with advanced cancer (49-51%). Whilst just over half (52.6%) felt confident discussing CIM with patients, only 10% felt they had sufficient knowledge to discuss …
Most respondents believed that CIM (87.9%) could benefit patients with cancer, and MC could benefit those with advanced cancer …
Cannabis use among recently treated cancer patients: perceptions and experiences.
Salz T, Meza AM, Chino F, Mao JJ, Raghunathan NJ, Jinna S, Brens J, Furberg H, Korenstein D. Salz T, et al. Support Care Cancer. 2023 Aug 31;31(9):545. doi: 10.1007/s00520-023-07994-y. Support Care Cancer. 2023. PMID: 37650961 Free PMC article.
PURPOSE: To characterize cannabis use among cancer patients, we aimed to describe 1) patterns of cannabis use across multiple cancer sites; 2) perceived goals, benefits, harms of cannabis; and 3) communication about cannabis. ...RESULTS: …
PURPOSE: To characterize cannabis use among cancer patients, we aimed to describe 1) patterns of cannabis use across mu …
Defining research priorities and needs in cancer symptoms for adults diagnosed with cancer: an Australian/New Zealand modified Delphi study.
Yenson VM, Amgarth-Duff I, Brown L, Caperchione CM, Clark K, Cross A, Good P, Landers A, Luckett T, Philip J, Steer C, Vardy JL, Wong AK, Agar MR. Yenson VM, et al. Support Care Cancer. 2023 Jul 3;31(7):436. doi: 10.1007/s00520-023-07889-y. Support Care Cancer. 2023. PMID: 37395859 Free PMC article.
PURPOSE: This study asked consumers (patients, carers) and healthcare professionals (HCPs) to identify the most important symptoms for adults with cancer and potential treatment interventions. METHODS: A modified Delphi study was conducted involving two rounds of electroni …
PURPOSE: This study asked consumers (patients, carers) and healthcare professionals (HCPs) to identify the most important symptoms for adult …
Cannabis use prevalence, patterns, and reasons for use among patients with cancer and survivors in a state without legal cannabis access.
McClure EA, Walters KJ, Tomko RL, Dahne J, Hill EG, McRae-Clark AL. McClure EA, et al. Support Care Cancer. 2023 Jun 29;31(7):429. doi: 10.1007/s00520-023-07881-6. Support Care Cancer. 2023. PMID: 37382737 Free PMC article.
PURPOSE: Cannabis use among patients with cancer is common, yet data are limited regarding use patterns, reasons for use, and degree of benefit, which represents an unmet need in cancer care delivery. ...METHODS: A cross-sectional survey of patients with c …
PURPOSE: Cannabis use among patients with cancer is common, yet data are limited regarding use patterns, reasons for use, and …
2,430 results